CA2965178C - Thiazolyl-containing compounds for treating proliferative diseases - Google Patents

Thiazolyl-containing compounds for treating proliferative diseases Download PDF

Info

Publication number
CA2965178C
CA2965178C CA2965178A CA2965178A CA2965178C CA 2965178 C CA2965178 C CA 2965178C CA 2965178 A CA2965178 A CA 2965178A CA 2965178 A CA2965178 A CA 2965178A CA 2965178 C CA2965178 C CA 2965178C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
certain embodiments
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2965178A
Other languages
English (en)
French (fr)
Other versions
CA2965178A1 (en
Inventor
Nathanael S. Gray
Sara Jean Buhrlage
Steven P. Treon
Hwan Geun Choi
Yuan Xiong
Guang Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2965178A1 publication Critical patent/CA2965178A1/en
Application granted granted Critical
Publication of CA2965178C publication Critical patent/CA2965178C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2965178A 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases Active CA2965178C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067178P 2014-10-22 2014-10-22
US62/067,178 2014-10-22
PCT/US2015/056899 WO2016065138A1 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Publications (2)

Publication Number Publication Date
CA2965178A1 CA2965178A1 (en) 2016-04-28
CA2965178C true CA2965178C (en) 2023-09-26

Family

ID=55761545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2965178A Active CA2965178C (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Country Status (7)

Country Link
US (3) US10112957B2 (OSRAM)
EP (2) EP3209648B1 (OSRAM)
JP (1) JP6788583B2 (OSRAM)
AU (1) AU2015335788B2 (OSRAM)
CA (1) CA2965178C (OSRAM)
IL (1) IL251790B (OSRAM)
WO (1) WO2016065138A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2015335788B2 (en) 2014-10-22 2020-07-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
MX380776B (es) * 2016-07-14 2025-03-12 Lilly Co Eli Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
KR102540515B1 (ko) * 2016-11-03 2023-06-05 코버스 파마슈티칼스, 인크. 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109265455B (zh) * 2018-11-09 2020-08-18 新发药业有限公司 一种达沙替尼的制备方法
JOP20220199A1 (ar) * 2020-02-26 2023-01-30 Daewoong Pharmaceutical Co Ltd طريقة لتحضير مشتقات أمين حلقي غير متجانس
US20230131830A1 (en) * 2020-03-06 2023-04-27 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
MXPA00010150A (es) 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
CA2338121A1 (en) 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
DE69912823T2 (de) 1998-09-25 2004-09-23 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US8030336B2 (en) 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
EP1831198B1 (en) 2004-12-22 2009-04-08 AstraZeneca AB Pyridine carboxamide derivatives for use as anticancer agents
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
RU2368602C2 (ru) * 2005-01-26 2009-09-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
US7375951B2 (en) * 2006-07-07 2008-05-20 Lutron Electronics Co., Inc. Load control device having a split enclosure
WO2007019191A2 (en) * 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
DK1957461T3 (en) 2005-11-14 2016-12-19 Genentech Inc Bisamidhæmmere the hedgehog-signalling
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
EP2183232B1 (en) * 2007-08-02 2013-03-06 Amgen, Inc Pi3 kinase modulators and methods of use
WO2009053854A2 (en) 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2009076373A1 (en) 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット,インコーポレイティド 置換アミド、その製造法及びBtkインヒビターとしての使用
KR20110049851A (ko) 2008-09-02 2011-05-12 베링거 인겔하임 인터내셔날 게엠베하 신규한 벤즈아미드, 이의 제조방법, 및 약제로서의 이의 용도
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
RU2012109233A (ru) 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
EP2519517B1 (en) * 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
MX340490B (es) 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
AU2012259333B2 (en) 2011-05-23 2017-06-08 Merck Patent Gmbh Pyridine-and pyrazine derivatives
KR101880966B1 (ko) 2011-06-10 2018-07-23 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR20140080528A (ko) 2011-10-03 2014-06-30 신젠타 파티서페이션즈 아게 살곤충 2­메톡시벤즈아미드 유도체
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
MX2014005289A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de piperazina alquilados.
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド C−jun−n−末端キナーゼ(jnk)の阻害剤
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
CN103405429A (zh) 2013-08-22 2013-11-27 中国药科大学 一类vegfr-2抑制剂及其用途
WO2015069287A1 (en) 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
AU2015335788B2 (en) 2014-10-22 2020-07-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases

Also Published As

Publication number Publication date
US20190119301A1 (en) 2019-04-25
EP3209648A1 (en) 2017-08-30
US20200165267A1 (en) 2020-05-28
US20170233411A1 (en) 2017-08-17
JP6788583B2 (ja) 2020-11-25
AU2015335788A1 (en) 2017-05-04
EP3715346B1 (en) 2024-01-03
IL251790B (en) 2019-08-29
EP3715346A1 (en) 2020-09-30
WO2016065138A1 (en) 2016-04-28
US10464949B2 (en) 2019-11-05
US10112957B2 (en) 2018-10-30
AU2015335788B2 (en) 2020-07-30
EP3209648A4 (en) 2018-07-25
CA2965178A1 (en) 2016-04-28
US10844077B2 (en) 2020-11-24
JP2017537886A (ja) 2017-12-21
EP3209648B1 (en) 2020-03-11
IL251790A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
CA2965178C (en) Thiazolyl-containing compounds for treating proliferative diseases
AU2016283105B2 (en) 4,6-pyrimidinylene derivatives and uses thereof
AU2015371251B2 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10342798B2 (en) Fused bicyclic pyrimidine derivatives and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA2996978A1 (en) Inhibitors of cyclin-dependent kinases
CA2936256A1 (en) Diazepane derivatives and uses thereof
CA2936871A1 (en) Dihydropteridinone derivatives and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
CA2988330C (en) 4,6-pyrimidinylene derivatives and uses thereof
US20230151001A9 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917

EEER Examination request

Effective date: 20200917